Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Patience is a key element of success.... B.Gates

<< Previous

Bullboard Posts

Next >>

Comment by Bigginvestoron Apr 20, 2021 3:21pm

254 Views

Post# 33030783

RE: Patience is a key element of success.... B.Gates

whisky11 wrote: We have to wait until management tell us about progress with the US government to finance the project.
Is there a private business willing to finance phase 1
When phase 1 starts and how long it will take. Because of urgency, is the project gonna be expedited
Until then $0.05-$0.10
On the bright side we all know R-107 works and is safe.
After successful phase 1we will get another dilemma what is better ,to buy white Ferrari with black interioror to buy black Ferrari with white interior.

lol I'm going for the Aston Martin

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property